5-Fluoro-2-(phenylthio)aniline | 329217-09-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 5-Fluoro-2-(phenylthio)aniline
• 英文别名: 5-fluoro-2-thiophenylaniline；5-Fluoro-2-phenylsulfanyl-phenylamine；5-fluoro-2-phenylsulfanylaniline
• CAS: 329217-09-6
• 化学式: C₁₂H₁₀FNS
• 分子量: 219.283
• InChiKey: KKBOAEOPDADJHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-Fluoro-2-(phenylthio)aniline 在 吡啶 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 16.5h， 生成 N-[5-fluoro-2-(phenylsulfinyl)phenyl]-1-benzofuran-2-sulfonamide
  参考文献：
  名称：

  BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS

  摘要：

  本发明涉及新型苯并呋喃-2-磺酰胺衍生物，制备它们的方法，含有它们的药物组合物以及它们作为化学受体调节剂的药用。

  公开号：

  US20130231338A1
• 作为产物：
  描述：

  2-氯-5-氟硝基苯 在 氯化铵 、 sodium hydroxide 、 锌 作用下， 以 甲醇 、 水 为溶剂， 反应 17.0h， 生成 5-Fluoro-2-(phenylthio)aniline
  参考文献：
  名称：

  BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS

  摘要：

  本发明涉及新型苯并呋喃-2-磺酰胺衍生物，制备它们的方法，含有它们的药物组合物以及它们作为化学受体调节剂的药用。

  公开号：

  US20130231338A1

文献信息

• ANTI-VIRAL COMPOUNDS
  申请人：Betebenner A. David

  公开号：US20070197558A1

  公开（公告）日：2007-08-23

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

  本发明公开了一种有效抑制丙型肝炎病毒（“HCV”）或其他病毒复制的化合物。本发明还涉及包含这些化合物的组合物、这些化合物与其他抗病毒或治疗剂的联合配方或联合给药、合成这些化合物的过程和中间体，以及使用这些化合物治疗HCV或其他病毒感染的方法。
• Anti-viral compounds
  申请人：Abbott Laboratories

  公开号：US07915411B2

  公开（公告）日：2011-03-29

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

  本发明揭示了一种有效抑制丙型肝炎病毒（“HCV”）或其他病毒复制的化合物。本发明还涉及包含这些化合物的组合物、这些化合物与其他抗病毒或治疗剂的共同配方或共同管理、合成这些化合物的过程和中间体，以及使用这些化合物治疗HCV或其他病毒感染的方法。
• Antiviral compounds
  申请人：Abbott Laboratories

  公开号：EP2345652A1

  公开（公告）日：2011-07-20

  The present invention is directed to the use of compounds effective in inhibiting replication of Hepatitis C virus ("HCV") or other viruses, tautomers of said compounds, or pharmaceutically acceptable salts of said compounds or tautomers, for the manufacture of a medicament for the treatment of HCV.

  本发明涉及使用能有效抑制丙型肝炎病毒（"HCV"）或其他病毒复制的化合物、所述化合物的同系物或所述化合物或同系物的药学上可接受的盐，制造治疗 HCV 的药物。
• Behavioral Approach to Nondyskinetic Dopamine Antagonists:  Identification of Seroquel
  作者：Edward J. Warawa、Bernard M. Migler、Cyrus J. Ohnmacht、Ann L. Needles、George C. Gatos、Frances M. McLaren、Cynthia L. Nelson、Karen M. Kirkland

  DOI：10.1021/jm000242+

  日期：2001.2.1

  A great need exists for antipsychotic drugs which will not induce extrapyramidal symptoms (EPS) and tardive dyskinesias (TDs). These side effects are deemed to be a consequence of nonselective blockade of nigrostriatal and mesolimbic dopamine D2 receptors. Nondyskinetic clozapine (1) is a low-potency D2 dopamine receptor antagonist which appears to act selectively in the mesolimbic area. In this work dopamine antagonism was assessed in two mouse behavioral assays: antagonism of apomorphine-induced climbing and antagonism of apomorphine-induced disruption of swimming. The potential for the liability of dyskinesias was determined in haloperidol-sensitized Cebus monkeys. Initial examination of a few close cogeners of 1 enhanced confidence in the Cebus model as a predictor of dyskinetic potential. Considering dibenzazepines, 2 was not dyskinetic whereas 2a was dyskinetic. Among dibenzodiazepines, 1 did not induce dyskinesias where as its N-2-(2-hydroxyethoxy)ethyl analogue 3 was dyskinetic. The emergence of such distinctions presented an opportunity. Thus, aromatic and N-substituted analogues of 6-(piperazin-1-yl)-11H-dibenz[b,e]azepines and 11-(piperazin-1-yl)dibenzo[b,f][1,4]thiazepines and -oxazepines were prepared and evaluated. 11-(4-[2-(2-Hydroxyethoxy)ethyl]piperazin-1-yl)dibenzo[b,f][1,4]thiazepine (23) was found to be an apomorphine antagonist comparable to clozapine. It was essentially nondyskinetic in the Cebus model. With 23 as a platform, a number of N-substituted analogues were found to be good apomorphine antagonists but all were dyskinetic.
• US7915411B2
  申请人：——

  公开号：US7915411B2

  公开（公告）日：2011-03-29